Payment overview · 2025
General Payments
$151.00
8 reported records · 5 companies
Healthcare provider profile · identity verified
Michael Louis Molinaro, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GLEN RIDGE, NJ · NPI 1144234634
Verified facts
What the public records show
CMS Open Payments records show Michael Louis Molinaro, MD received $151.00 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.48 | 37.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.23 | 24.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.26 | 13.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.00 | 13.2% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.03 | 11.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.00 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.41 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1215 | 340 |
| Amlodipine Besylate | Amlodipine Besylate | 657 | 186 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 555 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 494 | 129 |
| Alprazolam | Alprazolam | 427 | 107 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 88 |
| Simvastatin | Simvastatin | 302 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 278 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 73 |
| Metformin Hcl | Metformin Hcl | 246 | 79 |
| Losartan Potassium | Losartan Potassium | 235 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 186 | 44 |
| Lisinopril | Lisinopril | 182 | 52 |
| Allopurinol | Allopurinol | 160 | 39 |
| Sertraline Hcl | Sertraline Hcl | 160 | 41 |
| Metformin Hcl Er | Metformin Hcl | 153 | 51 |
| Methylprednisolone | Methylprednisolone | 141 | 117 |
| Omeprazole | Omeprazole | 140 | 42 |
| Azithromycin | Azithromycin | 139 | 126 |
| Irbesartan | Irbesartan | 120 | 34 |
| Januvia | Sitagliptin Phosphate | 114 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 35 |
| Furosemide | Furosemide | 103 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 98 | 71 |
| Lorazepam | Lorazepam | 97 | 21 |
| Potassium Chloride | Potassium Chloride | 92 | 24 |
| Famotidine | Famotidine | 91 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 43 |
| Enalapril Maleate | Enalapril Maleate | 82 | 21 |
| Eliquis | Apixaban | 81 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 21 |
| Ozempic | Semaglutide | 70 | 12 |
| Ezetimibe | Ezetimibe | 68 | 18 |
| Synthroid | Levothyroxine Sodium | 65 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 60 | 57 |
| Atenolol | Atenolol | 58 | 16 |
| Gabapentin | Gabapentin | 58 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 46 |
| Glimepiride | Glimepiride | 52 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 11 |
| Mirtazapine | Mirtazapine | 49 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 47 | 15 |
| Montelukast Sodium | Montelukast Sodium | 47 | 13 |
| Donepezil Hcl | Donepezil Hcl | 46 | 13 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 13 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 17 |
| Finasteride | Finasteride | 37 | 14 |
| Naproxen | Naproxen | 37 | 30 |
| Trazodone Hcl | Trazodone Hcl | 37 | 14 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Ramipril | Ramipril | 35 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Carvedilol | Carvedilol | 32 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Prednisone | Prednisone | 32 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 21 |
| Mometasone Furoate | Mometasone Furoate | 29 | 22 |
| Cephalexin | Cephalexin | 28 | 22 |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 21 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Aliskiren | Aliskiren Hemifumarate | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 16 |
| Azelastine Hcl | Azelastine Hcl | 22 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Desloratadine | Desloratadine | 17 | suppressed |
| Lipitor | Atorvastatin Calcium | 17 | suppressed |
| Bystolic | Nebivolol Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 12 |
| Mupirocin | Mupirocin | 13 | 11 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.00 · 8 records | Novo Nordisk Inc | Heplisav-B, Korlym, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error